Parsippany, NJ, March 24, 2026 (Yahoo Finance) -- Embecta has agreed to acquire Owen Mumford to strengthen its drug-delivery business. The transaction, valued at approximately $300 million, will add a range of injection and medical device products to Embecta’s portfolio. The deal is expected to enhance the company’s capabilities in supporting patients with chronic conditions. Read full article here .

Brisbane, CA, April 7, 2026 (ImpediMed) — ImpediMed has named Erik Anderson as its new chief executive officer. The leadership change is intended to guide the company’s strategic direction and support expansion of its medical technology portfolio. The appointment comes as ImpediMed focuses on advancing its commercial operations and growth initiatives. Read full article here .

San Diego, CA, April 7, 2026 (Yahoo Finance) -- Neurocrine Biosciences has outlined a transaction valued at approximately $2.9 billion aimed at expanding its therapeutic portfolio. The deal is designed to enhance the company’s pipeline with additional clinical-stage assets. The move supports Neurocrine’s strategy to drive long-term growth through targeted business development initiatives. Read full article here .